In a groundbreaking clinical trial led by Stanford Medicine and international collaborators, researchers have successfully restored partial vision in people with advanced age-related macular degeneration (AMD) using a tiny wireless eye implant and a pair of high-tech glasses. The study, published on October 20 in the New England Journal of Medicine, revealed that 27 out of 32 participants regained the ability to read within a year of receiving the device.
With the help of digital enhancements such as zoom and contrast adjustments, some patients achieved visual acuity equivalent to 20/42 vision, marking a major advancement in restoring sight for individuals with previously incurable blindness.
The PRIMA Device: A New Frontier in Vision Restoration
The innovative device, known as PRIMA, developed at Stanford Medicine, is the first prosthesis to restore functional or “form” vision—the ability to recognize shapes and patterns—in patients with irreversible vision loss.
“All previous prosthetic devices could only detect light, not form vision,” explained Dr. Daniel Palanker, Professor of Ophthalmology at Stanford and co-senior author of the study. “We are the first to provide true form vision.”
The research was co-led by Dr. José-Alain Sahel from the University of Pittsburgh School of Medicine and Dr. Frank Holz from the University of Bonn, Germany.
How the Technology Works
The PRIMA system consists of two components—a miniature camera mounted on glasses and a wireless retinal chip implanted at the back of the eye. The glasses capture real-time images and transmit them as infrared light signals to the chip. This chip, in turn, converts the infrared images into electrical impulses, which stimulate retinal neurons that remain intact despite the disease, effectively replacing lost photoreceptors.
Because the chip is photovoltaic, it requires no wires or external power source, operating entirely on light. This design allows seamless integration with the eye, unlike older prosthetic devices that depended on external cables. Patients can also continue using their natural peripheral vision alongside their new prosthetic central vision, enhancing navigation and spatial awareness.
Restoring Sight for Macular Degeneration Patients
Participants in the trial were adults over 60 suffering from geographic atrophy, an advanced form of AMD that destroys central vision. The implant was placed in the retina region where photoreceptors were lost. After about a month of recovery, patients began training with the glasses, which helped them gradually improve visual clarity over several months—similar to how cochlear implant users learn to interpret new auditory signals.
Of the 32 patients who completed the one-year trial, 27 regained reading ability, and 26 showed clinically significant improvements in visual acuity—reading at least two additional lines on an eye chart. On average, participants improved by five lines, and one patient gained twelve lines.
As reported by Stanford Medicine press release, the device helped patients read books, recognize food labels, and navigate public spaces. They could adjust contrast, brightness, and magnification—up to 12 times—through the glasses. About two-thirds of participants reported medium to high satisfaction with their visual improvements.
Managing Side Effects and Ensuring Safety
While the results were encouraging, 19 participants experienced temporary side effects such as ocular hypertension, retinal tears, and subretinal hemorrhage. However, none were life-threatening, and most resolved within two months.
Pioneering the Future of Artificial Vision
Currently, PRIMA provides only black-and-white vision, but Dr. Palanker’s team is developing software to introduce grayscale, which will enable patients to recognize faces—one of their most requested features.
“The top priority for patients is reading, followed closely by face recognition,” Palanker said. “Adding grayscale will make that possible.”
The researchers are also working on next-generation chips with smaller pixels and higher resolution. The current chip, with 100-micron pixels, contains 378 pixels in total. The upcoming version may include 10,000 pixels at just 20 microns each, offering sharper vision.
According to Palanker, this upgrade could help patients achieve 20/80 vision, and with electronic zoom, they might even reach 20/20 clarity.
Global Collaboration and Support
The study brought together scientists and clinicians from over 20 leading research institutions across Europe and the United States, including the University of Bonn, Moorfields Eye Hospital (London), Sorbonne Université (Paris), University of Rome Tor Vergata, and the University of California, San Francisco.
The project received funding from Science Corp., the National Institute for Health and Care Research (UK), Moorfields Eye Hospital NHS Foundation Trust, and the UCL Institute of Ophthalmology.
A Visionary Leap for the Future
After nearly two decades of research and innovation, PRIMA represents a major leap forward in retinal prosthetics, offering new hope for millions living with blindness caused by photoreceptor degeneration. As Palanker noted, “The device we imagined in 2005 now works remarkably well in patients. This is just the beginning of a new era in artificial vision.”